Company intelligence / Profile preview
Siren Biotechnology
San Francisco, California, United Statessirenbiotechnology.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
SRN-101, their lead asset for high-grade gliomas, has received both Orphan Drug and Rare Pediatric Disease designations from the FDA. Preclinical data has demonstrated potent anti-tumor effects in brain cancer models.
- Therapeutic areas
- Oncology
- Modalities
- AAV gene therapycytokine immunotherapyAAV immuno-gene therapy
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Catalent Inc. (for process development and cGMP manufacturing)
Beyond the preview
Go deeper on Siren Biotechnology.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Siren Biotechnology.